 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Approval of Zerit XR, a New Formulation That Allows Once-a-Day DosingDecember 31, 2002 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Today the Food and Drug Administration approved a new, extended release formulation of Zerit (stavudine, d4T) called Zerit XR. This extended-release formulation has been demonstrated to maintain measurable plasma concentrations for 24 hours after once-daily dosing. Zerit XR is indicated for the treatment of HIV in combination with other antiretrovirals. The recommended dose of Zerit XR is 100 mg once daily for individuals weighing at least 60 kg and 75 mg once daily for individuals weighing less than 60 kg. In a clinical study conducted in 783 treatment-na•ve, HIV-infected individuals Zerit® XR was comparable to the previously approved twice daily formulation of Zerit. In this randomized, controlled study, participants were randomized to either the extended release or standard formulation, in combination with lamivudine and efavirenz. The proportion of patients with HIV-RNA (viral load levels) below 400 copies/mL at 48 weeks was 79% and 76% for the extended release and immediate release-containing regimens, respectively. For viral load under 50, the response rates were 55% and 57% for the new and old formulations, respectively. The tolerability and safety profile of the new once daily, extended release formulation is comparable to that of the previously approved twice daily formulation. The study results were supported by a second, smaller study in 150 treatment na•ve patients. The full label will soon be available at the FDA Web site. Simply click "Z" in the index, and scroll to look for Zerit XR. Zerit XR is a product of the Bristol-Myers Squibb Company. A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!  This article was provided by U.S. Food and Drug Administration.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
